FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078752617> ?p ?o ?g. }

• W2078752617 endingPage "1093" @default.
• W2078752617 startingPage "1084" @default.
• W2078752617 abstract "While rifaximin was able to improve symptoms in patients with irritable bowel syndrome (IBS) in phase III trials, these results are yet to be repeated in phase IV studies.To evaluate the treatment response to rifaximin in IBS patients in a phase IV trial.IBS patients underwent lactulose hydrogen breath testing (LHBT). LHBT-positive patients were treated with rifaximin for 14 days. Prior to treatment as well as at week 4 and 14 following the start of rifaximin treatment, patients completed a questionnaire assessing symptom severity on a Likert scale from 0 to 10.One hundred and six of 150 IBS patients (71%) were LHBT-positive and treated with rifaximin. As assessed at week 4 following commencement of the therapy, rifaximin provided significant improvement of the following IBS-associated symptoms: bloating (5.5 ± 2.6 before the start of the treatment vs. 3.6 ± 2.7 at week 4, P<0.001), flatulence (5.0 ± 2.7 vs. 4.0 ± 2.7, P=0.015), diarrhoea (2.9 ± 2.4 vs. 2.0 ± 2.4, P=0.005) and abdominal pain (4.8 ± 2.7 vs. 3.3 ± 2.5, P<0.001). Overall well-being also significantly improved (3.9 ± 2.4 vs. 2.7 ± 2.3, P < 0.001). Similar improvements in IBS symptoms were obtained at week 14. Eighty-six per cent of patients undergoing repetitive LHBT (55/64) tested negative at week 4.We found a high percentage of LHBT-positive IBS patients. IBS-associated symptoms (bloating, flatulence, diarrhoea, pain) were improved for a period of 3 months following 2 weeks of treatment with rifaximin. We conclude that rifaximin treatment alleviates symptoms in LHBT-positive IBS patients." @default.
• W2078752617 created "2016-06-24" @default.
• W2078752617 creator A5008218383 @default.
• W2078752617 creator A5010594551 @default.
• W2078752617 creator A5014026215 @default.
• W2078752617 date "2012-11-16" @default.
• W2078752617 modified "2023-10-17" @default.
• W2078752617 title "Rifaximin treatment for the irritable bowel syndrome with a positive lactulose hydrogen breath test improves symptoms for at least 3 months" @default.
• W2078752617 cites W1918209772 @default.
• W2078752617 cites W1963986741 @default.
• W2078752617 cites W1972248676 @default.
• W2078752617 cites W1992348505 @default.
• W2078752617 cites W1995504800 @default.
• W2078752617 cites W2002324192 @default.
• W2078752617 cites W2009348105 @default.
• W2078752617 cites W2018343808 @default.
• W2078752617 cites W2019442793 @default.
• W2078752617 cites W2024601462 @default.
• W2078752617 cites W2033600566 @default.
• W2078752617 cites W2036459028 @default.
• W2078752617 cites W2040308416 @default.
• W2078752617 cites W2049004338 @default.
• W2078752617 cites W2056129681 @default.
• W2078752617 cites W2061675108 @default.
• W2078752617 cites W2061874852 @default.
• W2078752617 cites W2077005896 @default.
• W2078752617 cites W2086179308 @default.
• W2078752617 cites W2087956925 @default.
• W2078752617 cites W2093095026 @default.
• W2078752617 cites W2096023882 @default.
• W2078752617 cites W2100363885 @default.
• W2078752617 cites W2115895723 @default.
• W2078752617 cites W2115917215 @default.
• W2078752617 cites W2118451157 @default.
• W2078752617 cites W2120896017 @default.
• W2078752617 cites W2141397074 @default.
• W2078752617 cites W2149216059 @default.
• W2078752617 doi "https://doi.org/10.1111/apt.12087" @default.
• W2078752617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23066911" @default.
• W2078752617 hasPublicationYear "2012" @default.
• W2078752617 type Work @default.
• W2078752617 sameAs 2078752617 @default.
• W2078752617 citedByCount "54" @default.
• W2078752617 countsByYear W20787526172013 @default.
• W2078752617 countsByYear W20787526172014 @default.
• W2078752617 countsByYear W20787526172015 @default.
• W2078752617 countsByYear W20787526172016 @default.
• W2078752617 countsByYear W20787526172017 @default.
• W2078752617 countsByYear W20787526172018 @default.
• W2078752617 countsByYear W20787526172019 @default.
• W2078752617 countsByYear W20787526172021 @default.
• W2078752617 countsByYear W20787526172022 @default.
• W2078752617 countsByYear W20787526172023 @default.
• W2078752617 crossrefType "journal-article" @default.
• W2078752617 hasAuthorship W2078752617A5008218383 @default.
• W2078752617 hasAuthorship W2078752617A5010594551 @default.
• W2078752617 hasAuthorship W2078752617A5014026215 @default.
• W2078752617 hasBestOaLocation W20787526171 @default.
• W2078752617 hasConcept C126322002 @default.
• W2078752617 hasConcept C2775913212 @default.
• W2078752617 hasConcept C2775981797 @default.
• W2078752617 hasConcept C2776345142 @default.
• W2078752617 hasConcept C2776409635 @default.
• W2078752617 hasConcept C2776956441 @default.
• W2078752617 hasConcept C2777448540 @default.
• W2078752617 hasConcept C2778271842 @default.
• W2078752617 hasConcept C2778889925 @default.
• W2078752617 hasConcept C2780955771 @default.
• W2078752617 hasConcept C2780999109 @default.
• W2078752617 hasConcept C501593827 @default.
• W2078752617 hasConcept C71924100 @default.
• W2078752617 hasConcept C86803240 @default.
• W2078752617 hasConcept C89423630 @default.
• W2078752617 hasConcept C90924648 @default.
• W2078752617 hasConceptScore W2078752617C126322002 @default.
• W2078752617 hasConceptScore W2078752617C2775913212 @default.
• W2078752617 hasConceptScore W2078752617C2775981797 @default.
• W2078752617 hasConceptScore W2078752617C2776345142 @default.
• W2078752617 hasConceptScore W2078752617C2776409635 @default.
• W2078752617 hasConceptScore W2078752617C2776956441 @default.
• W2078752617 hasConceptScore W2078752617C2777448540 @default.
• W2078752617 hasConceptScore W2078752617C2778271842 @default.
• W2078752617 hasConceptScore W2078752617C2778889925 @default.
• W2078752617 hasConceptScore W2078752617C2780955771 @default.
• W2078752617 hasConceptScore W2078752617C2780999109 @default.
• W2078752617 hasConceptScore W2078752617C501593827 @default.
• W2078752617 hasConceptScore W2078752617C71924100 @default.
• W2078752617 hasConceptScore W2078752617C86803240 @default.
• W2078752617 hasConceptScore W2078752617C89423630 @default.
• W2078752617 hasConceptScore W2078752617C90924648 @default.
• W2078752617 hasIssue "11-12" @default.
• W2078752617 hasLocation W20787526171 @default.
• W2078752617 hasLocation W20787526172 @default.
• W2078752617 hasOpenAccess W2078752617 @default.
• W2078752617 hasPrimaryLocation W20787526171 @default.
• W2078752617 hasRelatedWork W1905583853 @default.
• W2078752617 hasRelatedWork W1978798905 @default.
• W2078752617 hasRelatedWork W1995504800 @default.

• next